Thursday, April 14, 2011

Biotech/ Biodefense Stock Trading Alert; Emergent Biosolutions (NYSE: EBS) Hits 52 Week High Biodefense Stocks Sector Snapshot; (OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (AMEX: PLX ), (NasdaqGM: SIGA)

Point Roberts, WA - April 14, 2011 - Investorideas.com, a leader in sector stock research including biotech and biodefense stocks issues a trading alert on Emergent Biosolutions, Inc. (NYSE: EBS) as it hit a 52 week high in Wednesday’s trading. The Company reported its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress.
Biotech/ Biodefense Stocks Sector Snapshot ( as of close April 14 th)
  • Aethlon Medical (OTCBB: AEMD) closed at $0.1036 on over 242,000 shares, with its 52 week range of $0.096 - 0.35
  • Dynasil Corporation (NASDAQ GM: DYSL) ended at $4.14, with a 52 week range of $ 2.35 - 7.48
  • Emergent Biosolutions, Inc. (NYSE: EBS ) closed at $24,68 hitting its 52 week high; $14.11 - 25.24
  • PharmAthene, Inc. (NYSE Amex: PIP) finished trading at $3.17, its 52 week range of $1.25 - 4.96
  • Protalix BioTherapeutics, Inc. (AMEX: PLX ) closed at $7.24, up 0.15 (2.12%)
  • Siga Technologies (NasdaqGM: SIGA ) ended trading at $13.4, up 0.48 (3.71%) on over 437,000 shares
Recent News:
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress
ROCKVILLE, Md.--- Emergent BioSolutions Inc. (NYSE: EBS ) announced that Fuad El-Hibri, its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress. The ViE awards showcase excellence and honor accomplishments of both individuals and companies in the global vaccine industry.
"This award is a testament to the collective efforts of the Emergent BioSolutions team, who on a daily basis and all over the world, lives out the corporate mission – to protect life,” said Mr. El-Hibri. "Our team shares a passion and commitment to make vital contributions to address unmet and underserved medical needs. It is an honor to be recognized for the work that we do.”
In selecting the winner for this category, the distinguished panel of judges evaluated the finalists based on their commitment to disease prevention and treatment, leadership, contribution to company performance, communication, and vision, industry influence, and achievements in company positioning and status.
Aethlon Medical (OTCBB: AEMD) Announces Multi-Target Exosome Assay Validation
SAN DIEGO - April 12, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc. (ESI) has validated the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal. In July 2010, ESI disclosed that it filed a patent relating to the development of an assay that would allow researchers to detect exosomes in blood and other fluids. In addition to research opportunities, Aethlon Medical plans to test ELLSA as a diagnostic to quantify the therapeutic capabilities of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the circulatory system of those afflicted with cancer. ESI is now preparing a market survey that will be provided to researchers to determine market demand and pricing for ELLSA as a research tool.
Full news: http://www.investorideas.com/CO/AEMD/news/2011/04121.asp
Biodefense Company Snapshots; Aethlon Medical (OTCBB: AEMD),
Aethlon Medical (OTCBB: AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
More: www.aethlonmedical.com
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Visit the Aethlon Medical (OTCBB: AEMD) showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Emergent Biosolutions, Inc. (NYSE: EBS )
Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders. www.emergentbiosolutions.com

About www.InvestorIdeas.com
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more Biodfense stocks at Investorideas.com
http://www.investorideas.com/bds/stock_list.asp
Research Biotech Stocks atInvestorideas.com
http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011     
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

A Broad-Spectrum Treatment Strategy to Address HIV, Hepatitis-C (HCV) and other Infectious Disease Conditions; Q&A with Aethlon Medical (OTCBB: AEMD) CEO, Jim Joyce

Point Roberts, WA. - April 14, 2011 � Investorideas.com, a leader in sector stock research presents a new interview in its series of biotech Q&A's, featuring Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD).
The Hemopurifier® from Aethlon Medical is a first-in-class medical device candidate to treat infectious disease. Human studies have documented that the Hemopurifier® can significantly reduce viral load in Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients in the absence of antiviral drugs. A study is currently underway to demonstrate the benefit of the Hemopurifier® as an adjunct to HCV drug therapy. Additional details can be accessed online at www.aethlonmedical.com
Q&A Interview
InvestorIdeas: How does your Hemopurifier® differ from drug therapies to treat infectious disease?
Mr. Joyce: Well, our approach is a complete departure from the consensus approach of introducing drug agents into the body to inhibit viral replication. As you are likely aware, these agents can have countering side effects or mechanisms of action that may not be fully understood. So, instead of adding agents into the body, our Hemopurifier® subtracts or removes viruses and other harmful particles from circulation without drug-related side effects. We think our therapeutic filtration approach could redefine the premise of how to treat infectious disease and we believe our strategy is far more innovative than another me-too drug inhibitor.
InvestorIdeas: Is a device that removes harmful particles from the body really considered to be innovative?
Mr. Joyce: The idea of a therapeutic filtration device that can remove harmful particles from circulation is not original. The basis of kidney dialysis, which keeps individuals with renal disease alive, is based on therapeutic filtration. However, like dialysis, previous therapeutic filtration strategies have sought to remove particles from circulation by molecule size, which is an indiscriminate approach that can also remove elements from circulation that are required for health. This factor has primarily limited the use of therapeutic filtration to niche markets. Our Hemopurifier® is truly innovative in the sense that we discriminate to selectively remove infectious viruses and other harmful particles from the entire circulatory system. It is this advancement that allows us to pursue opportunities in the much larger infectious disease and cancer markets.
InvestorIdeas: So it would seem your Hemopurifier® is positioned as a competitor to drug therapies.
Mr. Joyce: That is certainly not our intent. In fact, we expect to be an ally to the drug industry for several compelling reasons. First, if you really want to enhance or extend the benefit of drug therapies, you remove the strains of viruses that are causing drugs to fail and you do it without adding drug toxicity or interaction risks. But to fully unlock the capability of drug therapies you need to provide other complementary mechanisms that are beyond the reach of drugs. In that regard, we provide a strategy to address the toxins shed from viral surfaces to kill immune cells and particles known as exosomes that allow viruses to transport other disease-enhancing particles below the surveillance of the immune system. So our device in combination with drug therapy would seem to be a win-win scenario.
InvestorIdeas: What if a virus is not treatable with drug therapy?
Mr. Joyce: In reality, a vast majority of the viruses that are known to be infectious to man are not treatable with drugs. In scenarios that are life threatening, our Hemopurifer® is likely to be the sole strategy to address viral infections that are not treatable with drugs. For this reason, our Hemopurifier® is immensely valuable as new viruses like the coronavirus underlying the SARS outbreak of 2003 will emerge naturally in the future. We also face the looming threat of biological weapons purposely designed to defeat drug therapies. In either case, our Hemopurifier® provides a decision free first response that can augment the body's own immune response to such exposures, which is certainly more logical than an post-exposure strategy comprised of first identifying the virus that is killing people, and then establishing post-death research programs that may or may not yield a viable treatment candidate years after the fact.
InvestorIdeas: Thank you.
About Aethlon Medical ( OTCBB: AEMD )
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011       
800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011

Tuesday, April 12, 2011

Security Stocks; Visualant (OTCBB:VSUL) Subsidiary TransTech Systems Announces Access Card Programmer Incorporated in ID Card Printers

SEATTLE - April 12, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce that TransTech Systems has successfully incorporated an industry standard access card programmer into an identification card printer for production of personalized access control credentials.
Traditionally, access cards are pre-programmed by providers and shipped to the users for future use. At the time of card issuance, there is a two step process whereby the card is read by an access reader to get the pre-programmed number associated with the card and then the card is printed with the card holder's information. With TransTech's integration of Farpointe Data's Cards on the Go™ COG1000 directly into the printer, the process can be accomplished in one step. Further, the requirements for ordering pre-programmed stock and the related worries about the security of this stock before issuance are eliminated.
Cards on the Go™ COG-1000 is an access control credential programmer designed to give security access control professionals and system integrators the ability to program both proximity and contactless smartcard credentials. The Cards on the Go™ COG-1000 desktop solution includes a USB-based desktop programmer, a USB cable, programming software and 100 preloaded programming tokens. The Cards on the Go™ card printer based solution configuration will vary by printer manufacturer. OEM solutions for larger systems integrators may be available.
Adding Cards on the Go™ technology to identification card printer solutions provides a unique product offering for TransTech's security reseller channel. TransTech Systems is currently the only provider of this technology. The unit was debuted at the ISC West Security Industry trade show in Las Vegas last week. Full production is planned within sixty days.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
About Farpointe Data
Since 2003 Farpointe Data (www.farpointedata.com), a privately held company located in California�s Silicon Valley, has offered radio frequency identification (RFID) readers, cards and tags for access control. These advanced products span the frequency spectrum, each including a host of unique Farpointe-only features. These products include the 125-kHz Pyramid Series Proximity� line of proximity readers, cards and tags, the Delta™ line of multi-technology (combining 13.56-MHz & 125-kHz operation) contactless smartcard readers, cards and tags, as well as the 433-MHz Ranger™ line of long-range transmitters and receivers.
Farpointe's exacting RFID designs, superior manufacturing, competitive pricing and excellent performance have earned the trust of its partners, access control system manufacturers, and achieved recognition as the industry's leading independent manufacturer of readers, cards and tags.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) Announces Multi-Target Exosome Assay Validation

SAN DIEGO - April 12, 2011 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc. (ESI) has validated the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal. In July 2010, ESI disclosed that it filed a patent relating to the development of an assay that would allow researchers to detect exosomes in blood and other fluids. In addition to research opportunities, Aethlon Medical plans to test ELLSA as a diagnostic to quantify the therapeutic capabilities of the Aethlon Hemopurifier� to remove immunosuppressive exosomes from the circulatory system of those afflicted with cancer. ESI is now preparing a market survey that will be provided to researchers to determine market demand and pricing for ELLSA as a research tool.
"We are grateful to those organizations that collaborated in beta-testing the capabilities of ELLSA to detect exosomes, which are increasingly being recognized as particles that deplete immune cells or provide a mechanism to transport disease-enhancing factors below the surveillance of the immune system,� stated Aethlon CEO, Jim Joyce. "Additionally, the ESI ELLSA provides the potential for a near-term revenue stream that complements the therapeutic programs we are actively advancing at Aethlon Medical"
About Aethlon Medical
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
  1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
  2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
  3. Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
  4. Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011

Friday, April 8, 2011

Biotech/ Biodefense Sector Trading Alert Stocks Include; (OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (AMEX: PLX ), (NasdaqGM: SIGA

Point Roberts, WA- April 8, 2011 - Investorideas.com, a leader in investor sector research
including Biotech and Biodefense Stocks issues a trading alert on the sector for morning trading
April 8th. Stocks Include; (OTCBB: AEMD), (NASDAQ GM: DYSL), (NYSE Amex: PIP), (AMEX:
PLX and (NasdaqGM: SIGA ).

The iShares Nasdaq Biotechnology Index (NasdaqGM: IBB ) is trading up at 102.37, up 0.19
(0.19%).

Biotech/ Biodefense Stocks Sector Snapshot
Aethlon Medical (OTCBB: AEMD) trading at$0.12, up 0.01 (4.35%)
Dynasil Corporation (NASDAQ GM: DYSL) trading at$ 4.35, up 0.02 (0.46%)
Emergent Biosolutions, Inc. Com (NYSE: EBS ) trading at $24.70, down 0.04 (0.16%)
PharmAthene, Inc. (NYSE Amex: PIP) trading at $3.21, down 0.07 (2.12%)
Protalix BioTherapeutics, Inc. (AMEX: PLX ) trading at $6.63, up 0.20 (3.11%)
Siga Technologies (NasdaqGM: SIGA ) trading at $13.39, up 0.08 (0.60%) 10:32AM EDT

Research more Biodfense stocks at Investorideas.com
http://www.investorideas.com/bds/stock_list.asp
Research Biotech Stocks at Investorideas.com
http://www.investorideas.com/BIS/Stock_List.asp

Daily Finance’s recent article, “Inside Wall Street: Looking to the Bio-Defense Sector as
Nuclear Fears Mount”, notes - The sector attracted a lot of interest after 9/11 and a number of
companies emerged to develop protective biodefense drugs and products. But with the waning of
dark headlines about terrorist threats, investors have tended to put them on their low-priority list.
That may be about to change

Full article: http://www.dailyfinance.com/story/stock-picks/inside-wall-street-looking-to-bio-defense-sector-as-
nuclear-fea/19880106/

Biotech/ Biodefense Company Snapshots; Aethlon Medical (OTCBB: AEMD), Protalix
BioTherapeutics, Inc. (AMEX: PLX )

Aethlon Medical (OTCBB: AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer.
Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in
disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious
viruses and immunosuppressive proteins from the entire circulatory system. We recently
discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune
system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly
inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in
cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet
clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or
interaction risks to established and emerging treatment strategies.
More: www.aethlonmedical.com
Contacts:

James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com

Recent News: Shareholder Letter
http://www.investorideas.com/CO/AEMD/news/2011/04061.asp

Visit the Aethlon Medical (OTCBB: AEMD) showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD

Get added to the company’s news alerts:
http://www.investorideas.com/Resources/Newsletter.asp

Protalix BioTherapeutics, Inc. (AMEX: PLX )
Protalix is a biopharmaceutical company focused on the development and commercialization of
recombinant therapeutic proteins expressed through its proprietary plant cell based expression
system, ProCellEx™. Protalix's unique expression system presents a proprietary method for
developing recombinant proteins in a cost-effective, industrial-scale manner in an environment
free of mammalian components and viruses. Protalix's lead compound taliglucerase alfa,
an enzyme replacement therapy for the treatment of Gaucher disease, completed Phase III
development. To date, marketing applications have been submitted for taliglucerase alfa in the
United States, European Union, Brazil and Israel. Protalix's development pipeline also includes:
PRX-105, a pegylated recombinant human acetylcholinesterase in development for several
therapeutic and prophylactic indications, a biodefense program and an organophosphate-based
pesticide treatment program; PRX-102, a modified version of the recombinant human alpha-GAL-
A protein for the treatment of Fabry disease; an orally-delivered glucocerebrosidase enzyme that
is naturally encased in carrot cells, also for the treatment of Gaucher disease; and pr-antiTNF, a
biosimilar version of etanercept (Enbrel™) for the treatment of rheumatoid arthritis.

About www.InvestorIdeas.com

InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector
investing, including biotech stocks with its portal BiotechIndustryStocks.com.

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make

recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated
by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD )
Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five
thousand per month in 144 stock)Effective March 15, 2011
Aethlon Medical ( OTCBB:AEMD) :Certain of the statements herein may be forward-looking and involve risks and
uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially
different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

Thursday, April 7, 2011

Security Stocks; Tobin Smith of NBT Equity Group Interviews Visualant (OTCBB:VSUL) CEO

SEATTLE - April 7, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., announced today that Tobin Smith of NBT Equity Research LLC has released an interview with Visualant Chairman and Chief Executive Officer Ron Erickson. The interview can be accessed through the Visualant website at www.visualant.net or on the NBT Equity Research website at http://nbtequitiesresearch.com/company/visualant-vsul/nbt-tv.
NBT Equity Research LLC is a member of the NBT Equity Group LLC. They were founded by well known research analyst Tobin Smith. Tobin Smith is a contributing market analyst for Fox News Channel and a regular panelist on its highly rated "Bulls & Bears" weekly investment program.
On January 24, 2011, Tobin Smith issued a research report on Visualant which he supplemented on February 11, 2011. Both research reports can be accessed through the Visualant website at www.visualant.net.
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)

Wednesday, April 6, 2011

Security Stocks; TransTech Systems, a Subsidiary of Visualant (OTCBB:VSUL), to Distribute Farpointe Data's Access Card Programmer

SEATTLE - April 6, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly-owned subsidiary, TransTech Systems, Inc., is pleased to announce that TransTech Systems has been chosen to distribute Farpointe Data's new field programmer for access control credentials.
This week Farpointe Data has launched their new CoG-1000 Cards on the Go™ Multi-Technology Field Programmer. Farpointe Data manufactures access control card readers and credentials for many of the leading building access control systems in the market today. TransTech Systems, Farpointe Data's key distributor in the Americas, has been chosen to market the new CoG-1000 field access card programmer.
Scott Lindley, President of Farpointe Data, said, "Cards on the Go™ is a move to address a number of concerns of our customers, including the compressing of lead times and inventories of access credentials, while still providing the security. We are pleased to have TransTech Systems supporting their significant dealer channel with the new Cards on the Go™ solution."
Cards on the Go™ is a stand-alone access control credential programmer designed to give security access control professionals and system integrators the ability to program both proximity and contactless smartcard credentials. It is capable of producing one card at a time, as well as producing larger runs. The Cards on the Go™ solution includes a USB-based desktop programmer, a USB cable, programming software and 100 preloaded programming tokens. Various add-ons and enhancements to the Cards on the Go™ solution are planned for release during 2011. Additional tokens can be ordered through TransTech as well.
"Adding Farpointe Data's technology to our offering brought a very strong and reliable product line to our customer base," said Jeff Kruse, TransTech Systems General Manager. "The Cards on the Go™ solution is fairly unique in the current marketplace and should provide real opportunity for our channel partners."
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)